Endo announced that the Food and Drug Administration (FDA) has approved Belbuca (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long ...

DUBLIN , Feb. 22, 2016 /CNW/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP) (ENL.TO), today announced the availability of BELBUCA™ (buprenorphine) buccal film, the first ...

Endo announced the launch of Belbuca (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

More Than 115 Million Lives Now Have Preferred Access To BELBUCA In The U.S. RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing ...

New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility ...

Ohio leads the nation in opioid-related overdose deaths with 4,050 drug overdose deaths reported in 2016, a 33% increase from 2015 according to the Ohio Department of Health. The addition of BELBUCA ...

DUBLIN, Dec. 8, 2016 /PRNewswire/ -- Endo International plc (NASDAQ / TSX: ENDP) announced today that it has entered into an agreement with its partner, BioDelivery Sciences International, Inc. (BDSI) ...

BELBUCA' exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing BELBUCA', and ...

We issued an updated research report on BioDelivery Sciences International, Inc. BDSI on Nov 28. Shares of the company have surged 78.6% so far this year compared with the industry’s growth of 4.5%.